Sangamo Therapeutics, Inc.
http://www.sangamo.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sangamo Therapeutics, Inc.
Japan’s CEA Scheme: How It Works And Impact So Far
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
Finance Watch: Though Flush With Cash, Theseus Seeks Alternatives, Gets Two Quick Offers
Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.
BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval
Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
November US FDA User Fee Calendar: Takeda On Tap; Small Molecules For Cancer
Takeda hopes for good news on fruquintinib and TAK-755, while Bristol and SpringWorks share a goal date for their breakthrough-designated cancer treatments.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Ceregene, Inc
- Sangamo Biosciences, Inc.
- TxCell S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice